OpenAI Researcher Launches $2B Drug Company Via PowerPoint

Miles Wang, a researcher at OpenAI, is in talks to launch an AI drug discovery startup that has already been valued at $2 billion by investors who, it appears, have confused "in talks" with "has a product." The funding discussions represent a breathtaking vote of confidence in Wang's ability to exist as a founder, conduct meaningful drug discovery research, and simultaneously not actually have a company yet. This is what happens when the phrase "AI" meets the phrase "life sciences" in a late-stage bull market: investors stop asking questions and start writing checks against scenarios that haven't materialized.

What makes this valuation particularly spectacular is its relationship to empirical reality. Wang is currently employed at OpenAI. The startup he is theoretically launching does not appear to have employees, revenue, partnerships, proprietary datasets, clinical trials, or regulatory approval—the basic scaffolding of any actual pharmaceutical enterprise. Instead, it has "investor interest in applying AI to make breakthroughs in life sciences," which is venture-speak for "we read a McKinsey report and now we believe in magic." The $2 billion valuation is therefore a ceiling placed on absolute potential, divorced entirely from traction, progress, or the minor detail of whether the company has closed its seed round.

This follows a well-established pattern in frontier technology circles: recruit a credentialed technologist from a prestigious lab, announce their startup before it technically exists, price it like it has solved cancer, and watch the narrative calcify before anyone asks whether drug discovery is actually a software problem or a two-decade regulatory nightmare funded by billions in R&D. OpenAI alumni have launched companies before, which gives this particular fantasy some ancestral legitimacy. But ancestral legitimacy is precisely what allows investors to skip the part where they wait for, say, scientific validation.

The press release undoubtedly emphasizes "investor interest in applying AI to make breakthroughs in life sciences"—a phrase that translates to "we have not yet built anything, but AI is currently popular and pharmaceuticals are expensive, so statistically something might work." The beauty of this construction is its unfalsifiability: breakthroughs take decades, so the current absence of breakthroughs is not yet a failure condition. It's a roadmap.

History suggests that a $2 billion pre-product valuation in biotech or drug discovery is precisely the kind of bet that either becomes a lesson in startup humility or disappears into the portfolio graveyard without follow-on funding. Drug discovery is capital-intensive, approval-dependent, and timeline-hostile to venture-scale returns. The average pharmaceutical development cycle runs twelve to fifteen years and costs $2.6 billion per approved drug—a statistic that makes this pre-launch valuation look like either prophetic or delusional, with no middle ground.

What this deal really reflects is the current state of VC conviction: if a smart person from a successful AI company says they want to apply neural networks to a hard problem, the valuation starts at "2x their last company's Series A" and adjusts upward from there. The fact that drug discovery may not be a task that yields to the same techniques that make chatbots coherent is treated as a detail best addressed in the 2027 down round.

Miles Wang now has two options: prove the market right, or become a cautionary tale about what happens when you price optimism in billions before the company is technically open for business.